The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurooncol Adv
Auteurs principaux: Jackson, Sadhana, Baker, Eva H, Gross, Andrea M, Whitcomb, Patricia, Baldwin, Andrea, Derdak, Joanne, Tibery, Cecilia, Desanto, Jennifer, Carbonell, Amanda, Yohay, Kaleb, O’Sullivan, Geraldine, Chen, Alice P, Widemann, Brigitte C, Dombi, Eva
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486535/
https://ncbi.nlm.nih.gov/pubmed/32939452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa095
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires